| 证券代码 | NTGN.O |
| 证券名称 | Neon Therapeutics Inc |
| 证券类型 | 美股 |
| 上市场所 | 纳斯达克交易所 |
| 上市板块 | 主板 |
| 发行方式 | 公开发售 |
| 首发上市日 | 2018-06-27 |
| 首发价格(元) | 16 USD |
| 首发数量(股) | 6250000 |
| 首发募资额(元) | 100,000,000.00 USD |
| 首发主承销商 | Morgan Stanley & Co. LLC,Merrill Lynch, Pierce, Fenner & Smith I |
| 货币单位 | USD |
| 公司名称 | Neon Therapeutics, Inc. |
| 注册地址 | 美国特拉华州 |
| 办公地址 | 40 Erie Street, Suite 110, Cambridge, Massachusetts, USA |
| 成立日期 | 2013-10 |
| 董事会主席 | Cary G. Pfeffer |
| 公司属地 | United States 美国 |
| 公司网址 | www.neontherapeutics.com |
| 电话 | +1 (617) 337-4701 |
| 传真 | - |
| 公司简介 | Neon Therapeutics, Inc. is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens. Genetic mutations, which are a hallmark of cancer, can result in specific immune targets called neoantigens. The presence of neoantigens in cancer cells and their absence in normal cells makes them compelling, untapped targets for cancer therapy. By directing the immune system towards these targets, the company believe its neoantigen-targeted therapies will offer a new level of patient and tumor specificity in the field of cancer immunotherapy that will drive a strong risk-benefit profile to dramatically improve patient outcomes. |